Alberta Science and Technology Leadership Foundation

The issue of this study was evaluate the frequency of no-proliferate findings, the immunoreactions of the monoclonal Ki-67 antibody and estrogen receptor in contra lateral breast of patients treated of breast cancer and in use of 20mg tamoxifen daily for one year or more They were selected in Breast Pathology Unit in State University of Campinas and in Gynecology-Oncology Unit of Prefeitura Municipal de So Joo da Boa Vista. A descriptive study had been done, evaluating patients from April to June 2003. Patients with bilateral cancer, in use of any sexual hormones at least one year, difficult of communication to collect information, if tamoxifen had been interrupted up to 24 hours, in use of any anticoagulant agents, if the tissue hadn't been proper to histological evaluation and if we had found any malignant lesion, in any of this cases, the patients were excluded. A pilot trial with 13 patients was carried out. Biopsy-cut with gauge 14 needle has done in contra lateral breast of 44 patients. Some data were analyzed with the help of Fisher's exact test, and others variables were merely descriptive. The significance level was defined at 5%. We observed that around 82% of the patients have had no-proliferate findings and 100% of the Summary xi patients have had mild immunoreaction of monoclonal Ki-67 antibody. Around 70% of the patients have had a negative expression of estrogen receptor. The length of time of use of tamoxifen did not associate to no-proliferate findings, immunoreactions of monoclonal Ki-67 antibody or estrogen receptor. The body mass index (BMI) didn't associate to no-proliferate findings, immunoreactions of monoclonal Ki-67 antibody or estrogen receptor. The no-proliferate findings did not associate to Wolfe's parenchyma pattern in mammograms. We have concluded that the use of tamoxifen at least 1 year has shown around of 80% no-proliferate findings in opposite breast of breast cancer patients. In concern of expression of estrogen receptor, just 30% of patients have had positive expression.

Summary form only given. The ability to track quality dual-frequency P-code (code and phase) observables has been responsible for many exciting developments in global positioning system (GPS) geodesy and precision navigation. However, civilian users were confronted with the fact that P-code quality tracking will essentially disappear when the government enacts full time anti-spoofing (AS). A proprietary technique called P/W tracking that produces pure high-quality code and full-wavelength carrier phase measurements in the presence of AS is described. The P/W tracking technique is discussed and its performance is compared with other available, but inherently inferior, AS countermeasures. Results of the P/W tracking technique from data collected during periods where AS was on (and off) are presented to characterize receiver performance and prove its applicability in supporting P-code quality civilian tracking applications. Precise differential navigation software for providing subdecimeter positioning is also described.< <ETX xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&gt;</ETX>

The capabilities of Ashtech XII for differential GPS (Global Positioning System) are discussed. Differential algorithms and communication protocols to exchange differential information between receivers are included in the internal software of the receiver. Hence, there is no need for external computers to provide the protocol link. The all-in-view capability of the receivers makes them suitable for reference stations as well as remotes. Integration of ASHTECH XII with the vehicle tracking system (VTS) is presented. Differential GPS messages are transferred via the VTS communication link. The integration of the VTS and differential GPS has resulted in an accurate vehicle tracking and positioning system called differential GPS/VTS.< <ETX xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&gt;</ETX>